ZACHARY WHITTLE: Open Payments
NPI 1508492570 · MUSKEGON, MI. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,111 in 127 payments from 32 companies in 2025. Trend: 2023 $1,860 · 2024 $1,911 · 2025 $2,111
Food & beverage: $2,092Education: $19
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 12 | $271 |
| ABBVIE INC. | 20 | $270 |
| GlaxoSmithKline, LLC. | 19 | $248 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 14 | $226 |
| Novo Nordisk Inc | 10 | $145 |
| Amgen Inc. | 8 | $119 |
| E.R. Squibb & Sons, L.L.C. | 3 | $66 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 4 | $66 |
| Teva Pharmaceuticals USA, Inc. | 3 | $48 |
| Neurocrine BioSciences, Inc. | 2 | $45 |
Products named: REXULTI, CAPLYTA, TRELEGY ELLIPTA, VRAYLAR, OTEZLA, Ozempic, COBENFY, XIFAXAN.
Industry payments across MI — which companies pay providers there.
